LifeCore Biomedical Reports on Shareholder Vote Matters

TL;DR

LifeCore Biomedical filed an 8-K for a shareholder vote on Oct 29th.

AI Summary

LifeCore Biomedical, Inc. filed an 8-K on October 31, 2025, reporting on matters submitted to a vote of security holders as of October 29, 2025. The filing indicates a submission of matters to a vote, but does not specify the nature of the vote or any outcomes.

Why It Matters

This filing signals that LifeCore Biomedical, Inc. has held or is preparing to hold a shareholder vote, which could pertain to significant corporate actions or governance changes.

Risk Assessment

Risk Level: low — The filing is a standard procedural report on a shareholder vote without immediate financial implications or disclosed risks.

Key Players & Entities

• LIFECORE BIOMEDICAL, INC. (company) — Registrant
• October 29, 2025 (date) — Date of earliest event reported
• October 31, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of incorporation
• Chaska, Minnesota (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — ich registered Common stock, par value $0.001 per share LFCR The NASDAQ Global Select

Filing Documents

• lfcr-20251029.htm (8-K) — 48KB
• 0001005286-25-000138.txt ( ) — 162KB
• lfcr-20251029.xsd (EX-101.SCH) — 2KB
• lfcr-20251029_lab.xml (EX-101.LAB) — 21KB
• lfcr-20251029_pre.xml (EX-101.PRE) — 12KB
• lfcr-20251029_htm.xml (XML) — 3KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On October 29, 2025, Lifecore Biomedical, Inc. (the "Company") held its 2025 annual meeting of stockholders (the "Annual Meeting"). As of the close of business on September 2, 2025, the record date for the Annual Meeting (the "Record Date"), there were (i) 37,436,784 shares of the Company's common stock, par value $0.001 per share (the "Common Stock") outstanding and entitled to vote at the Annual Meeting, (ii) 46,593 shares of the Company's Series A Convertible Preferred Stock, par value $0.001 per share (the "Series A Preferred Stock") outstanding, (iii) 46,593 shares of Series A Preferred Stock entitled to vote on the Series A Preferred Directors (as defined below), and (iv) 46,593 shares of Series A Preferred Stock entitled to vote on an as-converted basis (voting together with the holders of shares of Common Stock as one class), subject to the applicable conversion limits, on the other applicable nominees and proposals (representing, on an as-converted basis, the equivalent of 7,131,735 shares of Common Stock). The three proposals presented to the stockholders of the Company at the Annual Meeting were: (1) To elect nine directors to serve for a term expiring at the next succeeding annual meeting of stockholders or until their successors are duly elected and qualified, with seven such directors to be elected by holders of the Common Stock and the Series A Preferred Stock, voting together as a single class, and two such directors to be elected solely by holders of the Series A Preferred Stock (the latter, the "Series A Preferred Directors"). (2) To ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. (3) To approve a non-binding advisory proposal approving the compensation of the Company's name executive officers. 1. Stockholders elected the nine director nominees and the voting results were as follows: D

View Full Filing

View this 8-K filing on SEC EDGAR